It was at an MM&M event back in late 2013 that I got my first glimpse of how this industry feels about big data.
Four data aces share their backgrounds, inspirations, and guiding philosophies
We asked some of the agency world's sharpest data people to answer a pair of questions about the future of data in and around pharma marketing. Here's what they had to say.
In the past, pharma hasn't used data effectively to engage its A-list HCPs. Five companies hope to change that.
Fueled by system-wide demand and facilitated by AI, the industry's lofty expectations around real-world evidence could soon be fulfilled
Roche to acquire Flatiron Health for $1.9B; FDA considers allowing pre-symptom Alzheimer's drug tests; Marijuana producer branches into pharma.
CMS forecasts prescription drug spending to hit $5.7T by 2026; Ipsen predicts cancer drug shopping spree; Omnicom numbers miss estimates on revenue.
The two organizations will partner on content including personal stories and expert advice.
In 2017, Interpublic reported a net income of $579 million, down 4.8% from the previous year.
IPG 2017 net income drops; Bristol-Myers Squibb inks $1.85 billion deal with Nektar on cancer drug; Merck halts final-stage Alzheimer's drug.
Daniel Carucci is joining the Interpublic Group firm full-time after serving as a consultant and in roles with the U.N. Foundation and the U.S. Navy.
The company is also looking to better combine its web and social media presence.
Zimprich joins from Honeywell, where he led global business communications.
Amazon moves into medical supply market; Big Pharma gets a tax cut; Former Celgene CEO plans Senate run.
There was so much bigger-picture coverage of pharma and healthcare in 2017 - pricing, Affordable Care Act reform and repeal - that it was easy to lose sight of everything else. PwC's Health Research Institute has used its annual look-ahead report to spotlight a handful of undercover trends.
The pharma company manufactures the well-known opioid OxyContin.
Healthcare providers may understand its importance, but across the board not many are ready to meet the requirements of the program QPP, according to a study.
As the evidence mounts that high-deductibles don't cause patients to shop or save for healthcare, payers are taking note.
White House limits guidance documents; Top executives exit Axovant; Carroll nominated as drug czar.
Study: Two prostate cancer drugs delay metastasis by two years; Budget deal funds CHIP for four years; Azar outlines Trump's drug pricing plans.